Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $431.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

WilmerHale advised Dyne in the offering.

The WilmerHale team consisted of capital markets team members Stuart Falber, Scott Lunin, Hilary Baker-Jennings, Sam Wizon and Brandon Hornlein, with assistance from Meghan Walsh on tax matters, Tim Silva and Andy Walsh on 1940 Act matters, and Heidi Treiber on Nasdaq matters, and with paralegal support from Mark Devine.